Role of probiotics in prevention of Candida infection in critically ill children

Mycoses

Volumn 56, Issue 3, 2013, Pages 204-211

  Kumar, Suresh ^a   Singhi, Sunit ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Candida; Candidemia; Colonisation; Paediatric intensive care unit; Probiotics

Indexed keywords

IMMUNOGLOBULIN A; PROBIOTIC AGENT;

BACTERIAL ENDOCARDITIS; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM BIFIDUM; BIFIDOBACTERIUM LONGUM; CANDIDEMIA; CANDIDIASIS; CRITICALLY ILL PATIENT; CYTOKINE PRODUCTION; DRUG SAFETY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FUNGAL COLONIZATION; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; INFECTION RISK; INTESTINE FLORA; INVASIVE CANDIDIASIS; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILLUS; LACTOBACILLUS CASEI; LACTOBACILLUS RHAMNOSUS; MUCOSAL IMMUNITY; MULTICENTER STUDY (TOPIC); NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SACCHAROMYCES BOULARDII; SACCHAROMYCES CEREVISIAE;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS, INVASIVE; CHILD; CRITICAL ILLNESS; FUNGEMIA; GASTROINTESTINAL TRACT; HUMANS; INTENSIVE CARE UNITS, PEDIATRIC; LACTOBACILLUS; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

CANDIDA; PICUS;

EID: 84876335791     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12021     Document Type: Review

References (89)

1. Steinbach WJ. Epidemiology of invasive fungal infections in neonates and children. Clin Microbiol Infect 2010; 16: 1321-7.
2. Zaoutis T. Candidemia in children. Curr Med Res Opin 2010; 26: 1761-8.
3. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27: 887-92.
4. Singhi S, Ray P, Mathew JL, Jayashree M. Nosocomial bloodstream infection in a pediatric intensive care unit. Indian J Pediatr 2008; 75: 25-30.
5. Neu N, Malik M, Lunding A et al. Epidemiology of candidemia at a Children's hospital, 2002 to 2006. Pediatr Infect Dis J 2009; 28: 806-9.
6. Filioti J, Spiroglou K, Panteliadis CP, Roilides E. Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome. Intensive Care Med 2007; 33: 1272-83.
7. Nguyen MH, Peacock JE Jr, Morris AJ et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996; 100: 617-23.
8. Pappas PG, Rex JH, Lee J et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-43.
9. Singhi SC, Reddy TC, Chakrabarti A. Candidemia in a pediatric intensive care unit. Pediatr Crit Care Med 2004; 5: 369-74.
10. Verduyn Lunel FM, Meis JF, Voss A. Nosocomial fungal infections: candidemia. Diagn Microbiol Infect Dis 1999; 34: 213-20.
11. Blyth CC, Palasanthiran P, O'Brien TA. Antifungal therapy in children with invasive fungal infections: a systematic review. Pediatrics 2007; 119: 772-84.
12. Salminen S, Benno Y, de Vos W. Intestinal colonisation, microbiota and future probiotics?Asia Pac J Clin Nutr 2006; 15: 558-62.
13. Schulze J, Sonnenborn U. Yeasts in the gut: from commensals to infectious agents. Dtsch Arztebl Int 2009; 106: 837-42.
14. Zaoutis TE, Prasad PA, Localio AR et al. Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin Infect Dis 2010; 51: e38-45.
15. Singhi S, Deep A. Invasive candidiasis in pediatric intensive care units. Indian J Pediatr 2009; 76: 1033-44.
16. Saiman L, Ludington E, Dawson JD et al. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J 2001; 20: 1119-24.
17. Singhi S, Rao DS, Chakrabarti A. Candida colonization and candidemia in a pediatric intensive care unit. Pediatr Crit Care Med 2008; 9: 91-5.
18. Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996; 22: S89-94.
19. Agvald-Ohman C, Klingspor L, Hjelmqvist H, Edlund C. Invasive candidiasis in long- term patients at a multidisciplinary intensive care unit: Candida colonization index, risk factors, treatment and outcome. Scand J Infect Dis 2008; 40: 145-53.
20. Charles PE, Dalle F, Aube H et al. Candida spp. colonization significance in critically ill medical patients: a prospective study. Intensive Care Med 2005; 31: 393-400.
21. Issa SY, Badran EF, Aqel KF, Shehabi AA. Epidemiological characteristics of Candida species colonizing oral and rectal sites of Jordanian infants. BMC Pediatr 2011; 11: 79.
22. Kicklighter SD, Springer SC, Cox T, Hulsey TC, Turner RB. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics 2001; 107: 293-8.
23. Tortorano AM, Biraghi E, Astolfi A et al. European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. J Hosp Infect 2002; 51: 297-304.
24. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220: 751-8.
25. Leon C, Ruiz-Santana S, Saavedra P et al. A bedside scoring system ('Candida score') for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006; 34: 730-7.
26. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Donowitz LG. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001; 345: 1660-6.
27. Ben-Ari J, Samra Z, Nahum E, Levy I, Ashkenazi S, Schonfeld TM. Oral amphotericin B for the prevention of Candida bloodstream infection in critically ill children. Pediatr Crit Care Med 2006; 7: 115-8.
28. Wainer S, Cooper PA, Funk E, Bental RY, Sandler DA, Patel J. Prophylactic miconazole oral gel for the prevention of neonatal fungal rectal colonization and systemic infection. Pediatr Infect Dis J 1992; 11: 713-6.
29. Austin NC, Darlow B. Prophylactic oral antifungal agents to prevent systemic Candida infection in preterm infants. Cochrane Database Syst Rev 2004; 1: CD003478.
30. McGuire W, Clerihew L, Austin N. Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev 2004; 1: CD003850.
31. Neely MN, Schreiber JR. Fluconazole prophylaxis in the very low birth weight infant: not ready for prime time. Pediatrics 2001; 107: 404-5.
32. Samonis G, Gikas A, Toloudis P et al. Prospective study of the impact of broad-spectrum antibiotics on the yeast flora of the human gut. Eur J Clin Microbiol Infect Dis 1994; 13: 665-7.
33. Bendel CM, Wiesner SM, Garni RM, Cebelinski E, Wells CL. Cecal colonization and systemic spread of Candida albicans in mice treated with antibiotics and dexamethasone. Pediatr Res 2002; 51: 290-5.
34. Agarwal R, Sharma N, Chaudhry R et al. Effects of oral Lactobacillus GG on enteric microflora in low-birth-weight neonates. J Pediatr Gastroenterol Nutr 2003; 36: 397-402.
35. Floch MH. The effect of probiotics on host metabolism: the microbiota and fermentation. J Clin Gastroenterol 2010; 44: S19-21.
36. Kligler B, Cohrssen A. Probiotics. Am Fam Physician. 2008; 78: 1073-8.
37. Jacobi CA, Schulz C, Malfertheiner P. Treating critically ill patients with probiotics: beneficial or dangerous?Gut Pathog 2011; 3: 2.
38. Chermesh I, Eliakim R. Probiotics and the gastrointestinal tract: where are we in 2005?World J Gastroenterol 2006; 12: 853-7.
39. Buts JP, Bernasconi P, Vaerman JP, Dive C. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci 1990; 35: 251-6.
40. Hamad M. Innate and adaptive antifungal immune responses: partners on an equal footing. Mycoses 2012; 55: 205-17.
41. Wagner RD, Pierson C, Warner T et al. Biotherapeutic effects of probiotic bacteria on candidiasis in immunodeficient mice. Infect Immun 1997; 65: 4165-72.
42. Wagner RD, Pierson C, Warner T, Dohnalek M, Hilty M, Balish E. Probiotic effects of feeding heat-killed Lactobacillus acidophilus and Lactobacillus casei to Candida albicans-colonized immunodeficient mice. J Food Prot 2000; 63: 638-44.
43. Murzyn A, Krasowska A, Augustyniak D, Majkowska-Skrobek G, Lukaszewicz M, Dziadkowiec D. The effect of Saccharomyces boulardii on Candida albicans-infected human intestinal cell lines Caco-2 and Intestin 407. FEMS Microbiol Lett 2010; 310: 17-23.
44. Krasowska A, Murzyn A, Dyjankiewicz A, Lukaszewicz M, Dziadkowiec D. The antagonistic effect of Saccharomyces boulardii on Candida albicans filamentation, adhesion and biofilm formation. FEMS Yeast Res 2009; 9: 1312-21.
45. Jawhara S, Poulain D. Saccharomyces boulardii decreases inflammation and intestinal colonization by Candida albicans in a mouse model of chemically-induced colitis. Med Mycol 2007; 45: 691-700.
46. Hilton E, Isenberg HD, Alperstein P, France K, Borenstein MT. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med 1992; 116: 353-7.
47. Reid G, Charbonneau D, Erb J et al. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunol Med Microbiol 2003; 35: 131-4.
48. Zwolinska-Wcislo M, Brzozowski T, Mach T et al. Are probiotics effective in the treatment of fungal colonization of the gastrointestinal tract? Experimental and clinical studies. J Physiol Pharmacol 2006; 57: S35-49.
49. Manzoni P, Mostert M, Leonessa ML et al. Oral supplementation with Lactobacillus casei subspecies rhamnosus prevents enteric colonization by Candida species in preterm neonates: a randomized study. Clin Infect Dis 2006; 42: 1735-42.
50. Romeo MG, Romeo DM, Trovato L et al. Role of probiotics in the prevention of the enteric colonization by Candida in preterm newborns: incidence of late-onset sepsis and neurological outcome. J Perinatol 2011; 31: 63-9.
51. Toya SP, Schraufnagel DE, Tzelepis GE. Candiduria in intensive care units: association with heavy colonization and candidaemia. J Hosp Infect 2007; 66: 201-6.
52. Chakrabarti A, Reddy TC, Singhi S. Does candiduria predict candidaemia?Indian J Med Res 1997; 106: 513-6.
53. Cannon JP, Lee TA, Bolanos JT, Danziger LH. Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases. Eur J Clin Microbiol Infect Dis 2005; 24: 31-40.
54. Rautio M, Jousimies-Somer H, Kauma H et al. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999; 28: 1159-60.
55. Horwitch CA, Furseth HA, Larson AM, Jones TL, Olliffe JF, Spach DH. Lactobacillemia in three patients with AIDS. Clin Infect Dis 1995; 21: 1460-2.
56. Salminen MK, Rautelin H, Tynkkynen S et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis 2004; 38: 62-9.
57. Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM. Lactobacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect 1999; 5: 290-2.
58. Salvana EM, Frank M. Lactobacillus endocarditis: case report and review of cases reported since 1992. J Infect 2006; 53: e5-10.
59. Kunz AN, Noel JM, Fairchok MP. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr 2004; 38: 457-8.
60. Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005; 115: 178-81.
61. Sullivan A, Nord CE. Probiotic lactobacilli and bacteraemia in Stockholm. Scand J Infect Dis 2006; 38: 327-31.
62. Salminen MK, Tynkkynen S, Rautelin H et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 2002; 35: 1155-60.
63. Rouge C, Piloquet H, Butel MJ et al. Oral supplementation with probiotics in very-low-birth-weight preterm infants: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2009; 89: 1828-35.
64. Kukkonen K, Savilahti E, Haahtela T et al. Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial. Pediatrics 2008; 122: 8-12.
65. Salonen JH, Richardson MD, Gallacher K et al. Fungal colonization of haematological patients receiving cytotoxic chemotherapy: emergence of azole-resistant Saccharomyces cerevisiae. J Hosp Infect 2000; 45: 293-301.
66. Hennequin C, Kauffmann-Lacroix C, Jobert A et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 2000; 19: 16-20.
67. Lherm T, Monet C, Nougiere B et al. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 2002; 28: 797-801.
68. Perapoch J, Planes AM, Querol A et al. Fungemia with Saccharomyces cerevisiae in two newborns, only one of whom had been treated with ultra-levura. Eur J Clin Microbiol Infect Dis 2000; 19: 468-70.
69. Piechno S, Seguin P, Gangneux JP. Saccharomyces boulardii fungal sepsis: beware of the yeast. Can J Anaesth 2007; 54: 245-6.
70. Vandenplas Y, Brunser O, Szajewska H. Saccharomyces boulardii in childhood. Eur J Pediatr 2009; 168: 253-65.
71. Munoz P, Bouza E, Cuenca-Estrella M et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005; 40: 1625-34.
72. Dinleyici EC, Eren M, Ozen M, Yargic ZA, Vandenplas Y. Effectiveness and safety of Saccharomyces boulardii for acute infectious diarrhea. Expert Opin Biol Ther 2012; 12: 395-410.
73. Erdeve O, Tiras U, Dallar Y. The probiotic effect of Saccharomyces boulardii in a pediatric age group. J Trop Pediatr 2004; 50: 234-6.
74. Canani RB, Cirillo P, Terrin G et al. Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ 2007; 335: 340.
75. Riaz M, Alam S, Malik A, Ali SM. Efficacy and safety of Saccharomyces boulardii in acute childhood diarrhea: a double blind randomised controlled trial. Indian J Pediatr 2012; 79: 478-82.
76. Samonis G, Falagas ME, Lionakis S et al. Saccharomyces boulardii and Candida albicans experimental colonization of the murine gut. Med Mycol 2011; 49: 395-9.
77. Cassone M, Serra P, Mondello F et al. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol 2003; 41: 5340-3.
78. Szajewska H, Mrukowicz JZ. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr 2001; 33: S17-25.
79. Sazawal S, Hiremath G, Dhingra U, Malik P, Deb S, Black RE. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo- controlled trials. Lancet Infect Dis 2006; 6: 374-82.
80. Guarino A, Albano F, Ashkenazi S et al. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: executive summary. J Pediatr Gastroenterol Nutr 2008; 46: 619-21.
81. Wagner RD, Warner T, Roberts L, Farmer J, Balish E. Colonization of congenitally immunodeficient mice with probiotic bacteria. Infect Immun 1997; 65: 3345-51.
82. Besselink MG, van Santvoort HC, Buskens E et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371: 651-9.
83. Honeycutt TC, El Khashab M, Wardrop RM 3rd et al. Probiotic administration and the incidence of nosocomial infection in pediatric intensive care: a randomized placebo-controlled trial. Pediatr Crit Care Med 2007; 8: 452-8.
84. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks?Am J Clin Nutr 2006; 83: 1256-64 quiz 446-7..
85. Egervarn M, Danielsen M, Roos S, Lindmark H, Lindgren S. Antibiotic susceptibility profiles of Lactobacillus reuteri and Lactobacillus fermentum. J Food Prot 2007; 70: 412-8.
86. Egervarn M, Roos S, Lindmark H. Identification and characterization of antibiotic resistance genes in Lactobacillus reuteri and Lactobacillus plantarum. J Appl Microbiol 2009; 107: 1658-68.
87. Timmerman HM, Koning CJ, Mulder L, Rombouts FM, Beynen AC. Monostrain, multistrain and multispecies probiotics - a comparison of functionality and efficacy. Int J Food Microbiol 2004; 96: 219-33.
88. Chapman CM, Gibson GR, Rowland I. Health benefits of probiotics: are mixtures more effective than single strains?Eur J Nutr 2011; 50: 1-17.
89. McNaught CE, Woodcock NP, Anderson AD, MacFie J. A prospective randomised trial of probiotics in critically ill patients. Clin Nutr 2005; 24: 211-9.